Acadian Asset Management LLC bought a new position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 58,385 shares of the company’s stock, valued at approximately $2,870,000. Acadian Asset Management LLC owned 0.14% of Pacira Pharmaceuticals as of its most recent filing with the SEC.
Other institutional investors have also recently modified their holdings of the company. Bouchey Financial Group Ltd bought a new position in Pacira Pharmaceuticals in the 3rd quarter worth $221,000. US Bancorp DE boosted its holdings in Pacira Pharmaceuticals by 40.7% in the 2nd quarter. US Bancorp DE now owns 6,038 shares of the company’s stock worth $194,000 after buying an additional 1,746 shares during the period. Seven Eight Capital LP bought a new position in Pacira Pharmaceuticals in the 3rd quarter worth $308,000. Cubist Systematic Strategies LLC boosted its holdings in Pacira Pharmaceuticals by 1,925.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock worth $214,000 after buying an additional 6,336 shares during the period. Finally, Xact Kapitalforvaltning AB bought a new position in Pacira Pharmaceuticals in the 2nd quarter worth $219,000.
Shares of PCRX stock opened at $49.52 on Friday. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -85.38 and a beta of 1.68. Pacira Pharmaceuticals Inc has a 52 week low of $26.95 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.95, a quick ratio of 7.83 and a current ratio of 8.66.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.40. The business had revenue of $83.45 million for the quarter, compared to analysts’ expectations of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. The business’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.11 EPS. As a group, equities analysts expect that Pacira Pharmaceuticals Inc will post -0.02 earnings per share for the current fiscal year.
PCRX has been the subject of several recent analyst reports. Royal Bank of Canada set a $55.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, September 19th. Canaccord Genuity set a $49.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, October 2nd. Wedbush set a $85.00 target price on shares of Pacira Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, August 6th. Stifel Nicolaus initiated coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 13th. They issued a “sell” rating and a $41.00 target price for the company. Finally, ValuEngine downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $52.28.
In other Pacira Pharmaceuticals news, Director Gary W. Pace bought 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were purchased at an average cost of $51.29 per share, for a total transaction of $205,160.00. Following the transaction, the director now owns 28,319 shares of the company’s stock, valued at $1,452,481.51. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David M. Stack sold 33,062 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $47.32, for a total transaction of $1,564,493.84. The disclosure for this sale can be found here. Insiders have sold a total of 41,502 shares of company stock worth $1,968,214 over the last 90 days. Corporate insiders own 5.90% of the company’s stock.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Further Reading: What is an Initial Public Offering (IPO)?
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.